Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13209411 | 0.78 | PKM (0.31) | PKM | |
| SCHEMBL8744682 | 0.78 | KDM4E (0.35) | — | |
| SCHEMBL13003439 | 0.76 | PKM (0.30) | PKM | |
| SCHEMBL21720189 | 0.74 | MEN1 (0.40) | — | |
| SCHEMBL21721364 | 0.74 | — | — | |
| SCHEMBL21721711 | 0.74 | GAA (0.31) | — | |
| SCHEMBL23398676 | 0.74 | PKM (0.33) | PKM | |
| SCHEMBL21720329 | 0.74 | — | — | |
| SCHEMBL23403671 | 0.74 | PKM (0.36) | PKM | |
| SCHEMBL21720181 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192720-A1 | MACROCYCLIC COMPOUNDS | ZENO MANAGEMENT, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192720-A1 | MACROCYCLIC COMPOUNDS | ZENO MANAGEMENT, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20220144854-A1 | MACROCYCLIC COMPOUNDS | ZENO MANAGEMENT, INC. | 2022-05-12 | — | — | US | disclosed |
| US-20220106343-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2022-04-07 | — | — | US | disclosed |
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | PKM 2118/4885 |
| US-20220106343-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, ICOSLG | PKM 843/4885 |
| US-20230192720-A1 | MACROCYCLIC COMPOUNDS | MCL1, BCL2A1, BCL2L1 | PKM 2553/4885 |
| US-20220144854-A1 | MACROCYCLIC COMPOUNDS | MCL1, BCL9, CYC1 | PKM 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.